AbbVie Surges on FDA Approval of Decnupaz for Rare Blood Cancer and European Nod for Migraine Therapy
Key Insights
AbbVie (search) shares rose 3.5% following FDA approval of Decnupaz (search) (pivekimab sunirine) for blastic plasmacytoid dendritic cell neoplasm (search) (BPDCN), a rare and aggressive blood cancer, marking the company's first ADC approved for a blood cancer indication.
The European Commission granted approval for AQUIPTA (atogepant) as an acute treatment for migraine (search), transforming it into a dual-threat therapy already approved for migraine prevention.
The UK drug-cost watchdog recommended AbbVie (search)'s ovarian cancer (search) therapy Elahere for NHS availability, further expanding the drug's commercial reach in a hard-to-treat indication.
AbbVie (search) Inc. (NYSE: ABBV) shares climbed 3.5% on Thursday, closing at $224.81 after trading as high as $224.99, driven by a confluence of positive regulatory milestones and favorable analyst revisions. The stock's upward movement reflects growing investor confidence in the company's oncology and neuroscience pipelines, anchored by the recent FDA approval of Decnupaz (search) and European Commission authorization for AQUIPTA.
The company, which reported stronger-than-expected quarterly earnings of $2.65 per share on $15 billion in revenue — beating consensus estimates by $0.06 — has seen its market capitalization reach approximately $397.19 billion.
FDA Approval of Decnupaz (search) Validates Oncology ADC Strategy
The FDA approved Decnupaz (search) (pivekimab sunirine) for adults with blastic plasmacytoid dendritic cell neoplasm (search) (BPDCN), a rare and aggressive blood cancer. This approval is significant as it marks AbbVie (search)'s first antibody-drug conjugate (ADC) approved for a blood cancer indication, validating the company's oncology strategy and expanding its market presence in a critical therapeutic area.
The approval is being viewed by analysts as a validation of AbbVie (search)'s broader oncology ADC strategy, boosting confidence in the company's longer-term cancer pipeline.
European Commission Approves AQUIPTA for Acute Migraine (search) Treatment
The European Commission granted approval for AQUIPTA (atogepant) as an acute treatment for migraine (search). This regulatory success transforms AQUIPTA into a dual-threat therapy, having already been approved for migraine prevention. The decision positions AbbVie (search) to capture a larger share of the neurology market in a key international territory and is expected to enhance revenue opportunities within the company's neuroscience franchise.
Elahere Gains UK NHS Recommendation
Further bolstering positive sentiment, the UK drug-cost watchdog recommended AbbVie (search)'s ovarian cancer (search) therapy, Elahere, for NHS availability. This recommendation expands access in a hard-to-treat cancer indication and reinforces the drug's commercial potential in international markets.
Analyst Upgrades Reflect Optimism
Several prominent research firms have adjusted their outlook on AbbVie (search). Rothschild & Co Redburn (search) raised its price target from $265 to $284 while maintaining a Buy rating. Piper Sandler (search) increased its price objective from $294 to $298 and reiterated an "overweight" rating. Guggenheim reaffirmed a "buy" rating with a $249 price target, while Evercore set a $235 target.
According to MarketBeat, AbbVie (search) holds a consensus rating of "Moderate Buy" with an average target price of $253.43. Three analysts have rated the stock with a Strong Buy, sixteen have assigned a Buy rating, and six have issued a Hold rating.
Pipeline Developments and Clinical Momentum
AbbVie (search) continues to advance multiple clinical programs, including ABBV-647, ABBV-932, and upadacitinib. However, the company also ended an early lung cancer trial for ABBV-647, trimming one future oncology upside lever. The broader pipeline momentum, including recent positive clinical trial data presentations at the 2026 ASCO meeting, appears to offset that concern for now.
The company's diverse and robust pipeline spans immunology, neuroscience, and oncology, reinforcing the long-term growth outlook that has contributed to the positive investor reaction.